Literature DB >> 12904931

Inhibitory effect of 5-fluorouracil on human cytochrome P(450) isoforms in human liver microsomes.

Ji-Young Park1, Kyoung-Ah Kim.   

Abstract

OBJECTIVE: A number of case reports have been described regarding drug interactions with 5-fluorouracil (5-FU) and co-administered drugs. However, little is known regarding the inhibitory potential of 5-FU on the metabolism of co-administered drugs by cytochrome P(450) (CYP). The aim of the present study was to elucidate the inhibitory effect of 5-FU on CYP isoforms using human liver microsomes.
METHODS: The inhibitory effect of 5-FU on CYP1A2, CYP2C9, CYP2C19, CYP2C8, CYP2E1, CYP2D6, and CYP3A4 activities was examined with specific probe drugs in human liver microsomes.
RESULTS: 5-FU showed little or no inhibitory effect on CYP-catalyzed reactions in human liver microsomal preparations.
CONCLUSION: 5-FU has no inhibitory effect on CYP isoforms or drug metabolism causing drug interaction with 5-FU. The mechanism that causes drug interaction between co-administered drugs and 5-FU may not be related to direct CYP inhibition by 5-FU.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12904931     DOI: 10.1007/s00228-003-0641-z

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  25 in total

1.  Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms.

Authors:  J W Ko; N Sukhova; D Thacker; P Chen; D A Flockhart
Journal:  Drug Metab Dispos       Date:  1997-07       Impact factor: 3.922

2.  Modulation of the expression on constitutive rat hepatic cytochrome P450 isozymes by 5-fluorouracil.

Authors:  A Afsar; C Lee; D S Riddick
Journal:  Can J Physiol Pharmacol       Date:  1996-02       Impact factor: 2.273

3.  Warfarin-5-FU interaction--a consecutive case series.

Authors:  J M Kolesar; C L Johnson; B L Freeberg; J D Berlin; J H Schiller
Journal:  Pharmacotherapy       Date:  1999-12       Impact factor: 4.705

4.  Biotransformation of chlorzoxazone by hepatic microsomes from humans and ten other mammalian species.

Authors:  M H Court; L L Von Moltke; R I Shader; D J Greenblatt
Journal:  Biopharm Drug Dispos       Date:  1997-04       Impact factor: 1.627

5.  Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation.

Authors:  K E Thummel; D D Shen; T D Podoll; K L Kunze; W F Trager; C E Bacchi; C L Marsh; J P McVicar; D M Barr; J D Perkins
Journal:  J Pharmacol Exp Ther       Date:  1994-10       Impact factor: 4.030

6.  Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: mechanism of drug interaction between TCAs and phenytoin.

Authors:  Jae-Gook Shin; Ji-Young Park; Min-Jung Kim; Ji-Hong Shon; Young-Ran Yoon; In-June Cha; Sang-Seop Lee; Se-Wook Oh; Sang-Woo Kim; David A Flockhart
Journal:  Drug Metab Dispos       Date:  2002-10       Impact factor: 3.922

7.  Effect of 5-fluorouracil on the anticoagulant activity and the pharmacokinetics of warfarin enantiomers in rats.

Authors:  Qingyu Zhou; Eli Chan
Journal:  Eur J Pharm Sci       Date:  2002-10       Impact factor: 4.384

8.  Effect of quinidine on the dextromethorphan O-demethylase activity of microsomal fractions from human liver.

Authors:  F Broly; C Libersa; M Lhermitte; P Bechtel; B Dupuis
Journal:  Br J Clin Pharmacol       Date:  1989-07       Impact factor: 4.335

9.  Effects of 5-fluorouracil treatment on rat liver microsomal enzymes.

Authors:  I Stupans; D A Richards; M T McClure
Journal:  Xenobiotica       Date:  1995-01       Impact factor: 1.908

10.  Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man.

Authors:  D Sesardic; A R Boobis; B P Murray; S Murray; J Segura; R de la Torre; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1990-06       Impact factor: 4.335

View more
  5 in total

1.  Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes.

Authors:  Kyoung-Ah Kim; Jaegul Chung; Dong-Hae Jung; Ji-Young Park
Journal:  Eur J Clin Pharmacol       Date:  2004-09-08       Impact factor: 2.953

2.  Duloxetine improves oxaliplatin-induced neuropathy in patients with colorectal cancer: an open-label pilot study.

Authors:  Ya-Hsu Yang; Jen-Kou Lin; Wei-Shone Chen; Tzu-Chen Lin; Shung-Haur Yang; Jeng-Kai Jiang; Shih-Ching Chang; Yuan-Tzu Lan; Chun-Chi Lin; Chueh-Chuan Yen; Cheng-Hwai Tzeng; Wei-Shu Wang; Huey-Ling Chiang; Chung-Jen Teng; Hao-Wei Teng
Journal:  Support Care Cancer       Date:  2011-08-04       Impact factor: 3.603

3.  Inhibition of human gastric carcinoma cell growth by atofluding derivative N3-o-toluyl-fluorouracil.

Authors:  Jian Liu; Wen-Fang Xu; Shu-Xiang Cui; Yong Zhou; Yun-Xia Yuan; Ming-Hui Chen; Ruo-Han Wang; Ruo-Yan Gai; Masatoshi Makuuchi; Wei Tang; Xian-Jun Qu
Journal:  World J Gastroenterol       Date:  2006-11-14       Impact factor: 5.742

4.  Variations in the Blood Phenytoin Levels during Long-Term Combined Treatment with S-1 and Phenytoin.

Authors:  Yutaka Negoro; Takashi Higashi; Hiroaki Matsuoka; Kyohei Watanabe; Toshiaki Igarashi; Yuichiro Kayano; Ryoichi Yano; Toshiaki Nakamura; Mikio Masada
Journal:  Case Rep Oncol       Date:  2014-09-26

5.  Interaction between paliperidone extended release and TS-1(®), an oral anticancer drug containing a 5-fluorouracil derivative, in a schizophrenic patient.

Authors:  Norio Yasui-Furukori; Kojiro Hashimoto; Kazutoshi Kubo; Tetsu Tomita
Journal:  Neuropsychiatr Dis Treat       Date:  2013-03-03       Impact factor: 2.570

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.